Oregon is currently home to 1212 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome
NCT05035030
Recruiting
The purpose of this study is to assess the long-term safety and effectiveness of odevixibat in participants with Alagille syndrome (ALGS). The participants of this study will have ALGS a rare genetic disorder that can affect multiple organ systems of the body including the liver, heart, skeleton, eyes and kidneys. Common symptoms, which often develop during the first three months of life, include blockage of the flow of bile from the liver (cholestasis), yellowing of the skin and mucous membran... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: Oregon Health State University, Portland, Oregon
Conditions: Alagille Syndrome
Register for Updates
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
NCT04567420
Recruiting
A randomized, Phase II trial of circulating tumor DNA-guided second line Adjuvant therapy for high Residual risk, Estrogen Receptor positive, HER-2 negative breast cancer (DARE)
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Breast Cancer
Register for Updates
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
NCT03471260
Recruiting
This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating patients with IDH1-mutated hematologic malignancies. Venetoclax and ivosidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Acute Myeloid Leukemia, Hematopoietic and Lymphoid System Neoplasm, Myelodysplastic Syndrome
Register for Updates
Anesthetics and Analgesics in Children
NCT03427736
Recruiting
The purpose of this study is to characterize the pharmacokinetic (PK) and safety profile of anesthetics and analgesics in children and adolescents.
Gender:
ALL
Ages:
Between 0 years and 17 years
Trial Updated:
07/29/2025
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Anesthesia, Pain
Register for Updates
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
NCT00271180
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: Not set, Portland, Oregon
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Register for Updates
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
NCT06868290
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/28/2025
Locations: Oregon Health Sciences University, Portland, Oregon
Conditions: ANCA Associated Vasculitis (AAV)
Register for Updates
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06655896
Recruiting
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/28/2025
Locations: Oregon Health Sciences University, Portland, Oregon
Conditions: Scleroderma, Diffuse
Register for Updates
A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN)
NCT06581198
Recruiting
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) versus Standard of Care (SOC) in patients with systemic lupus erythematosus (SLE) with active, refractory lupus nephritis (LN).
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/28/2025
Locations: Oregon Health Sciences University, Portland, Oregon
Conditions: Lupus Erythematosus, Systemic, Lupus Nephritis
Register for Updates
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients
NCT06496178
Recruiting
This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Site 26, Portland, Oregon
Conditions: Head and Neck Squamous Cell Carcinoma
Register for Updates
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629
Recruiting
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/28/2025
Locations: Oregon Health and Science University (OHSU), Portland, Oregon
Conditions: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Register for Updates
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
NCT06116916
Recruiting
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: EyeHealth Northwest, Portland, Oregon
Conditions: Diabetic Macular Edema (DME)
Register for Updates
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
NCT06111235
Recruiting
This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followed by surveillance for the treatment of participants with IR-NMIBC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Oregon Urology Insititute, Springfield, Oregon
Conditions: Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer, Urothelial Carcinoma
Register for Updates